Purple Biotech’s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

The study was designed as Bayesian to evaluate the potential benefit of the experimental arm vs SoC and is not powered for …
(Orginal – Story lesen…)